GlassScriptPhysician profile
William B Funk
NPI 1598796286
$5,721.05
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,059 · 2020: $1,311 · 2021: $1,598 · 2022: $1,019 · 2023: $649 · 2024: $84.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $554 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $554.15 |
| Education | $179.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $903.52 | 2019-2023 | Farxiga |
| Lilly USA, LLC | $544.94 | 2019-2023 | Mounjaro |
| Merck Sharp & Dohme LLC | $451.73 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $319.92 | 2019-2022 | |
| Pfizer INC. | $287.84 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $286.63 | 2019-2022 | |
| Abbvie INC. | $273.56 | 2021-2023 | |
| Esperion Therapeutics, INC. | $252.04 | 2020-2021 | |
| Astellas Pharma US INC | $243.39 | 2022-2023 | Veozah, Myrbetriq |
| Amgen INC. | $229.60 | 2019-2022 | |
| Novo Nordisk INC | $196.85 | 2020-2024 | Ozempic, Rybelsus, Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $172.04 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $164.75 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.94 | 2022-2023 | |
| Avanir Pharmaceuticals, INC. | $125.90 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $124.56 | 2019-2023 | |
| Jazz Pharmaceuticals INC. | $115.14 | 2021-2022 | |
| Eisai INC. | $107.29 | 2020-2021 | |
| Adlon Therapeutics L.P. | $87.16 | 2019-2021 | |
| Genentech USA, INC. | $87.06 | 2019-2021 | |
| Glaxosmithkline, LLC. | $66.59 | 2019-2023 | Bexsero, Shingrix |
| Ironshore Pharmaceuticals INC. | $65.81 | 2019 | |
| Idorsia Pharmaceuticals US INC | $57.40 | 2022-2023 | Quviviq |
| Vbi Vaccine (Delaware) INC. | $57.24 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $52.91 | 2020-2021 | |
| Lundbeck LLC | $51.64 | 2022-2023 | Abilify Maintena |
| Supernus Pharmaceuticals, INC. | $44.11 | 2022 | |
| Allergan, INC. | $42.60 | 2020 | |
| Shire North American Group INC | $34.10 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.78 | 2019 | |
| Seqirus USA INC | $29.14 | 2021-2022 | |
| Corium, LLC | $25.44 | 2023 | Azstarys |
| Abbott Laboratories | $25.42 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $20.59 | 2021 | |
| Amarin Pharma, INC. | $16.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Funk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.